Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Debt (2023 - 2025)

Historic Total Debt for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $11.0 million.

  • Spyre Therapeutics' Total Debt fell 5545.68% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 5545.68%. This contributed to the annual value of $25.1 million for FY2024, which is 170431.65% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Total Debt of $11.0 million as of Q3 2025, which was down 5545.68% from $59.9 million recorded in Q2 2025.
  • Spyre Therapeutics' Total Debt's 5-year high stood at $164.4 million during Q2 2023, with a 5-year trough of $1.4 million in Q4 2023.
  • Moreover, its 3-year median value for Total Debt was $17.9 million (2024), whereas its average is $34.2 million.
  • Per our database at Business Quant, Spyre Therapeutics' Total Debt plummeted by 9839.4% in 2024 and then soared by 216893.94% in 2025.
  • Spyre Therapeutics' Total Debt (Quarter) stood at $1.4 million in 2023, then surged by 1704.32% to $25.1 million in 2024, then plummeted by 56.06% to $11.0 million in 2025.
  • Its Total Debt stands at $11.0 million for Q3 2025, versus $59.9 million for Q2 2025 and $42.8 million for Q1 2025.